Immunitybio announces execution of $75 million equity financing with an institutional investor

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. the company entered into a securities purchase agreement for a registered direct offering with a single institutional investor, providing for the issuance of common stock of immunitybio as well as warrants for the purchase of additional shares of common stock of immu.
IBRX Ratings Summary
IBRX Quant Ranking